#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

New method for semiquantitative evaluation of 123I-MIBG in neuroblastoma – calculation of total retention score


Authors: Igor Černý;  Jiří Prášek;  Helena Kašpárková
Authors‘ workplace: Klinika nukleární medicíny, Masarykova Univerzita a FN Brno
Published in: NuklMed 2014;3:62-66
Category: Original Article

Overview

Introduction:
Semiquantitative evaluation of 123I-MIBG accumulation in pediatric neuroblastoma make it possible to quantify answer to therapy and to assess prognosis – ability to achieve complete remission. Semiquantitative scores Curie and SIOPEN are mostly used nowadays. Japanese authors introduced a new method in 2012; it is based on the calculation of total retention score (TMRR). We evaluated this method in our department.

Material and methods:
We evaluated retrospectively 10 patients (5 boys, 5 girls, age 0 to 7 years); we performed 20 examinations with time interval of 2 to 12 months between initial and follow-up examination. Planar whole-body images were performed 4 and 24 hours after injection of 123I-MIBG. Total retention score based on total whole body counts was calculated for all images and compared to Curie and SIOPEN scores.

Results:
We detected decline of TMRR (on average 8,11 %) in 6/10 pts. Decline of Curie score was on average 50,76 % and SIOPEN score 56,23 % in these patients. Two pts had increase level of TMRR, effect of therapy was minimal, their finding did not almost change. Last two pts had also increase of TMRR even if Curie and SIOPEN scores declined significantly.

Conclusion:
Based on our resluts we believe that the proposed method calculating total retention score in evaluation of 123I-MIBG accumulation in padiatric neuroblastoma can serve only as a complementary method and cannot replace current semiquantitative methods.

Key words:
neuroblastoma, 123I-MIBG, quantification


Sources

1. Vik TA, Pfluger T, Kadota R et al. 123I-MIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatr Blood Cancer 2009;52:784–790

2. Kushner BH, Yeh SD, Kramer K et al. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082–1086

3. Messina JA, Cheng SC, Franc Bl et al. Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (MIBG) scans in patients with relapsed neuroblastoma. Pediatr Blood Cancer 2006;47:865–874

4. Sano Y, Okuyama C, Iehara T et al. New semi-quantitative 123I-MIBG estimation method compared with scoring system in follow-up of advanced neuroblastoma: utility of total MIBG retention ratio versus scoring method. Ann Nucl Med 2012;26:462–470

5. Brodeur GM. Neuroblastoma – biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203–216

6. Mazánek P, Bajčiová V, Šterba J et al. Novinky v diagnostice a léčbě neuroblastomu. Onkológia 2008;3:257–261

7. Maris JM, Hogarty MD, Bagatell R et al. Neuroblastoma. Lancet 2007;369:2106–2120

8. Ady N, Zucker JM, Asselain B et al. A new 123I-MIBG whole body scan scoring method - application to the prediction of the response of metastases to induction chemotherapy in stage IV neuroblastoma. Eur J Cancer 1995;31A:256–261

9. Lewington V, Bar Sever Z, Lynch T et al. Development of a new, semi-quantitative I-123 MIBG reporting method in high risk neuroblastoma. Eur J Nucl Med Mol Imaging 2009;36S:334(A)

10. Matthay KK, Shulkin B, Ladenstein R et al. Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer 2010;102:1319–1326

11. Suc A, Lumbroso J, Rubie H et al. Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system. Cancer 1996;77:805–811

12. Matthay KK, Edeline V, Lumbroso J et al. Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma. J Clin Oncol. 2003;21:2486–2491

Labels
Nuclear medicine Radiodiagnostics Radiotherapy
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#